Published in Ther Adv Psychopharmacol on December 01, 2012
Risks associated with the non-medicinal use of cannabis. Dtsch Arztebl Int (2015) 1.90
Neuropsychological performance in adolescent marijuana users with co-occurring alcohol use: A three-year longitudinal study. Neuropsychology (2015) 0.84
Medicinal Cannabis: In Vitro Validation of Vaporizers for the Smoke-Free Inhalation of Cannabis. PLoS One (2016) 0.78
WHY NOT POT?: A Review of the Brain-based Risks of Cannabis. Innov Clin Neurosci (2016) 0.77
Effect of cannabis smoking on lung function and respiratory symptoms: a structured literature review. NPJ Prim Care Respir Med (2016) 0.75
Structural imaging for addiction medicine: From neurostructure to neuroplasticity. Prog Brain Res (2015) 0.75
Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (1992) 16.31
Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature (1990) 13.60
Molecular characterization of a peripheral receptor for cannabinoids. Nature (1993) 13.45
Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet (2007) 11.27
International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev (2002) 8.50
Schizophrenia. Lancet (2009) 8.14
Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol (1995) 8.09
Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol (1988) 5.54
Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther (1997) 5.20
Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry (2005) 4.85
Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience (1998) 4.39
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. Pharmacol Rev (2010) 4.31
The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol (2007) 3.16
Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ (2002) 3.06
Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ (2004) 2.93
Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther (1996) 2.90
The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev (2005) 2.90
The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology (2004) 2.87
Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol (2002) 2.80
Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ (2002) 2.74
High-potency cannabis and the risk of psychosis. Br J Psychiatry (2009) 2.41
Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol (2009) 2.23
Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation (2004) 2.15
Cannabinoid pharmacology. Pharmacol Rev (1986) 2.15
Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study: naturalistic study [corrected]. Br J Psychiatry (2010) 2.08
Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J (2006) 2.01
Cognitive and subjective dose-response effects of acute oral Delta 9-tetrahydrocannabinol (THC) in infrequent cannabis users. Psychopharmacology (Berl) (2002) 1.84
Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry (2009) 1.69
Neuroimaging predictors of transition to psychosis--a systematic review and meta-analysis. Neurosci Biobehav Rev (2010) 1.65
The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes (Lond) (2006) 1.64
Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology (2009) 1.62
Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. J Neurosci (2002) 1.61
Prevalence and correlates of cannabis use in developed and developing countries. Curr Opin Psychiatry (2007) 1.59
Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine. Chem Biodivers (2007) 1.57
A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses (2005) 1.55
Alkylamides from Echinacea are a new class of cannabinomimetics. Cannabinoid type 2 receptor-dependent and -independent immunomodulatory effects. J Biol Chem (2006) 1.54
A community survey of adverse effects of cannabis use. Drug Alcohol Depend (1996) 1.51
Marijuana smoking vs cannabinoids for glaucoma therapy. Arch Ophthalmol (1998) 1.49
Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr Med Chem (2010) 1.49
Potency of delta 9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. J Forensic Sci (2008) 1.44
Quantitation of cannabinoid CB1 receptors in healthy human brain using positron emission tomography and an inverse agonist radioligand. Neuroimage (2009) 1.42
Modulation of mediotemporal and ventrostriatal function in humans by Delta9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis. Arch Gen Psychiatry (2009) 1.40
Cannabis and anxiety: a critical review of the evidence. Hum Psychopharmacol (2009) 1.40
Cannabis and psychosis/schizophrenia: human studies. Eur Arch Psychiatry Clin Neurosci (2009) 1.37
The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med (2009) 1.36
Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol (2010) 1.31
In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor. J Pharmacol Exp Ther (2001) 1.31
Being stoned: a review of self-reported cannabis effects. Drug Alcohol Rev (2003) 1.30
Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. Eur J Pharmacol (2001) 1.29
Cannabidiol interferes with the effects of delta 9 - tetrahydrocannabinol in man. Eur J Pharmacol (1974) 1.25
Neural basis of Delta-9-tetrahydrocannabinol and cannabidiol: effects during response inhibition. Biol Psychiatry (2008) 1.24
Cannabis-induced psychosis-like experiences are associated with high schizotypy. Psychopathology (2006) 1.23
The inheritance of chemical phenotype in Cannabis sativa L. Genetics (2003) 1.22
Targeting dopamine D2 and cannabinoid-1 (CB1) receptors in rat nucleus accumbens. J Comp Neurol (2006) 1.22
Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: sibling analysis and proband follow-up. Arch Gen Psychiatry (2010) 1.21
A historical overview of chemical research on cannabinoids. Chem Phys Lipids (2000) 1.20
Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis. Neuropharmacology (2008) 1.20
Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: interactions with tobacco and cannabis use. Br J Psychiatry (2007) 1.19
A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol Cancer Ther (2011) 1.17
Independent versus substance-induced major depressive disorder in substance-dependent patients: observational study of course during follow-up. J Clin Psychiatry (2006) 1.16
Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase. J Med Chem (1997) 1.15
Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being. Psychol Med (2011) 1.14
Cannabidiol potentiates pharmacological effects of Delta(9)-tetrahydrocannabinol via CB(1) receptor-dependent mechanism. Brain Res (2007) 1.14
Antipsychotic effect of cannabidiol. J Clin Psychiatry (1995) 1.13
Regulation of nausea and vomiting by cannabinoids. Br J Pharmacol (2011) 1.10
The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. Eur J Pharmacol (2006) 1.10
Detection of heteromers formed by cannabinoid CB1, dopamine D2, and adenosine A2A G-protein-coupled receptors by combining bimolecular fluorescence complementation and bioluminescence energy transfer. ScientificWorldJournal (2008) 1.08
Hashish. I. The structure of cannabidiol. Tetrahedron (1963) 1.07
Morbid risk of schizophrenia for relatives of patients with cannabis-associated psychosis. Schizophr Res (1995) 1.06
Looking for the role of cannabinoid receptor heteromers in striatal function. Neuropharmacology (2008) 1.06
Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes. Handb Exp Pharmacol (2011) 1.05
Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. J Clin Psychopharmacol (2004) 1.05
Cannabinoid receptor agonists are mitochondrial inhibitors: a unified hypothesis of how cannabinoids modulate mitochondrial function and induce cell death. Biochem Biophys Res Commun (2007) 1.00
Outcomes of occasional cannabis use in adolescence: 10-year follow-up study in Victoria, Australia. Br J Psychiatry (2010) 0.99
Cannabinoid receptors CB1 and CB2 form functional heteromers in brain. J Biol Chem (2012) 0.96
Endocannabinoids and pregnancy. Clin Chim Acta (2010) 0.94
Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice. Eur J Pharmacol (2005) 0.93
Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1. FASEB J (2011) 0.92
Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis: AKT1 and DAT1 genotype modulates the effects of δ-9-tetrahydrocannabinol on midbrain and striatal function. Mol Psychiatry (2012) 0.92
Modulation of auditory and visual processing by delta-9-tetrahydrocannabinol and cannabidiol: an FMRI study. Neuropsychopharmacology (2011) 0.90
Effects of marihuana in laboratory animals and in man. Br J Pharmacol (1974) 0.90
Increasing delta-9-tetrahydrocannabinol (Δ-9-THC) content in herbal cannabis over time: systematic review and meta-analysis. Curr Drug Abuse Rev (2012) 0.89
Sex, drugs, and cognition: effects of marijuana. J Psychoactive Drugs (2010) 0.89
Early cannabis use and schizotypal personality disorder symptoms from adolescence to middle adulthood. Schizophr Res (2012) 0.88
Cardiovascular and metabolic considerations in prolonged cannabinoid administration in man. J Clin Pharmacol (1982) 0.88
Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review. BMC Neurol (2009) 0.88
Imaging the neural effects of cannabinoids: current status and future opportunities for psychopharmacology. Curr Pharm Des (2009) 0.87
Are early-onset cannabis smokers at an increased risk of depression spells? J Affect Disord (2012) 0.86
CB1 Cannabinoid Receptor Expression in the Striatum: Association with Corticostriatal Circuits and Developmental Regulation. Front Pharmacol (2012) 0.86
Gut feelings about the endocannabinoid system. Neurogastroenterol Motil (2011) 0.85
Glutamatergic antipsychotic drugs: a new dawn in the treatment of schizophrenia? Ther Adv Psychopharmacol (2011) 0.83
A comparison of independent depression and substance-induced depression in cannabis-, cocaine-, and opioid-dependent treatment seekers. Am J Addict (2011) 0.82
Psychopharmacology of the endocannabinoids: far beyond anandamide. J Psychopharmacol (2011) 0.81
Cannabidiol affects the expression of genes involved in zinc homeostasis in BV-2 microglial cells. Neurochem Int (2011) 0.81
Cannabis-induced psychotic-like experiences are predicted by high schizotypy. Confirmation of preliminary results in a large cohort. Psychopathology (2008) 0.81
Methods for clinical research involving cannabis administration. Methods Mol Med (2006) 0.80
Cannabinoid receptors and their role in the regulation of the serotonin transporter in human placenta. Am J Obstet Gynecol (1999) 0.80
Comparative studies in man and in laboratory animals on 8 - and 9 -trans-tetrahydrocannabinol. Pharmacology (1973) 0.80
Cannabinoids and intestinal motility: welcome to CB2 receptors. Br J Pharmacol (2004) 0.80
Subjective effects of cannabis before the first psychotic episode. Aust N Z J Psychiatry (2009) 0.77